Estrella Immunopharma IncESLA
Price$0.47

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$10MTTM through 30 Jun 2026
Free Cash Flow -$9.4MTTM through 30 Jun 2026

Margins

Current

Returns

134.7%ROE

Balance Sheet Health

Debt / Equity0.00x
Current Ratio0.24x
Net Debt-$1.9Mnet cash position
Cash & Equivalents$100K

Quality Metrics

Altman Z-Score-52.94
Piotroski F-Score1 / 9
Earnings-Beat Rate33.3%

Multi-Year Trend

Diluted EPS-$0.25TTM
'21'23'24'25
FY2025: $-0.35

Dividend

No dividend

Capital Allocation

R&D Spend$7M

Segment Performance

SegmentRevenueYoYOutlook
Immunotherapy R&D$0
View details

Focus remains on advancing the clinical development of lead candidate EB103 and expanding clinical sites.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.